Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence.
|
31388720 |
2020 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed whether these polymorphisms are associated with cerebrospinal fluid AD biomarkers including total tau (t-tau), phosphorylated tau proteins (p-tau181, p-tau199, and p-tau231), amyloid-β42 (Aβ42), and visinin-like protein 1 (VILIP-1) to test possible relationships of specific genotypes and pathological levels of CSF AD biomarkers.
|
31771069 |
2020 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
No association of ARHL with CSF or brain Aβ levels was found.
|
31118310 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This may indicate that Aβ levels in the CSF are affected significantly by ventriculomegaly and not as much by pathophysiological pathways characteristic for each dementia entity.
|
29324921 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of Aβ and tau imaging in AD brain and CSF as well as blood biomarkers is shortly summarized.
|
30605056 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) biomarkers amyloid-β1-42 peptide (Aβ1-42) and tau were used in order to differentiate AD from SNAP.
|
31201430 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to such hypothesis, this cross-sectional study tested, in PD patients, the association between levels of PA and well-known risk factors for PDD, such as mood disorders and amyloid-β42 CSF content.
|
30746564 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, 51 patients (n = 32 mild cognitive impairment/mild dementia-AD, n = 19 moderate/severe dementia-AD) diagnosed according to clinical-biological criteria (CSF biomarkers and amyloid-PET) and 29 controls (with negative amyloid-PET) underwent neuropsychological and 3T-MRI examinations.
|
31491594 |
2019 |
Amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The potential for E22P-Aβ as a CSF biomarker of cerebral Aβ plaques should be investigated.
|
31688040 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neither amyloid-PET nor CSF biomarkers could discriminate short-term converters from non-converters.
|
30927601 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The core AD cerebrospinal fluid (CSF) biomarker toolbox include amyloid β (Aβ42 and the Aβ42/40 ratio) reflecting brain amyloidosis, total tau (T-tau) reflecting neurodegeneration intensity, and phosphorylated tau (P-tau) that is related to tau pathology.
|
31699324 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CSF levels of 42-amyloid-β, total and phosphorylated tau, α-synuclein and reciprocal ratios were measured in a group of 46 PD patients compared to 37 gender/age-matched controls and correlated with standard clinical scores for motor and non-motor features.
|
30348495 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we employed NII measures in conjunction with cerebrospinal fluid (CSF) biomarker classification (for β-amyloid (Aβ) and neurodegeneration) to evaluate 200 participants in an ongoing study of memory and aging.
|
30901713 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study comprises 33 consecutive patients with suspected cognitive decline that underwent lumbar puncture for CSF biomarker analysis and Amyloid-PET/CT within the diagnostic evaluation of memory impairment.
|
30735665 |
2019 |
Amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The amyloid (A), tau (T), neurodegeneration (N) Research Framework emphasizes brain imaging and CSF measures relevant to disease diagnosis and staging and can be applied to drug development and clinical trials.
|
30747416 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of this study were to (i) evaluate the analytical performance of the Lumipulse G β-Amyloid 1-42 (restandardized to Certified Reference Materials), β-Amyloid 1-40, total Tau, and pTau 181 assays on the fully automated LUMIPULSE G600II; (ii) compare CSF biomarker results of the Lumipulse G assays with the established manual ELISA assays (INNOTEST®) from the same company (Fujirebio); and (iii) establish cut-off values and the clinical performance of the Lumipulse G assays for AD diagnosis.
|
31759396 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the cognitive profile of healthy individuals with increased Cardiovascular Risk Factors, Aging and Dementia (CAIDE) dementia risk score and to explore whether this association is related to vascular burden and CSF biomarkers of amyloidosis and neurodegeneration.
|
29898969 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To perform a meta-analysis of 4 core CSF biomarkers (β-amyloid [Aβ]42, Aβ40, total tau [t-tau], and phosphorylated tau [p-tau]) to assess which of these are most altered in sporadic cerebral amyloid angiopathy (CAA).
|
29386280 |
2018 |
Amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In an asymptomatic at-risk cohort, elevated CSF Aβ (with or without elevated tau) was associated with greater rates of cognitive decline, with the specific pattern of decline varying across cognitive measures.
|
29523644 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When using the core CSF biomarkers (Aβ42, total Tau and phosphorylated Tau), 30% of the patients fell into the high-AD-likelihood (HL) group (both amyloid and neurodegeneration markers positive), 30% into the low-AD-likelihood group (all biomarkers negative), 28% into the suspected non-Alzheimer pathophysiology (SNAP) group (only neurodegeneration markers positive) and 12% into the isolated amyloid pathology group (only amyloid-positive).
|
29558986 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirms strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.
|
29171991 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, episodic disturbances can diminish CSF cerebral flow circulation increasing deposition in cerebral parenchyma of contrary metabolic products (e.g. beta Amyloid), possibly having a causal influence on senile dementia.
|
30037601 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared CSF levels of biomarkers of amyloidosis (Aβ<sub>1-42</sub>) and neurodegeneration (p-Tau<sub>181</sub>) in individuals with aMCI and with subjective cognitive impairment (SCI) in order to ascertain diagnostic accuracy and predict the odds ratio associated with aMCI.
|
29017912 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients were classified as normal, amyloidosis (A+/N-), amyloidosis and neurodegeneration (A+/N+) or suspected non-AD pathophysiology (SNAP), according to their CSF levels of biomarkers.
|
29966201 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF proteins associated with AD clinical stages and progression can complement Aβ and tau markers to inform neurodegeneration.
|
30253800 |
2018 |